Monday, 17 August 2026European Markets
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise AI Agent Rollout Outpaces Data Trust and Readiness
Enterprise adoption of agentic AI is accelerating fast — Siemens deepening its NVIDIA partnership for self-verifying agentic AI in chip design, Manulife expanding its Microsoft AI-governance partnership, and a wave of infrastructure launches (NVIDIA GPU-accelerated data processing, Dell exascale storage, new AI chip generations) — even as a new Google Cloud survey shows the underlying data foundation isn't ready: companies have AI access to only 45% of their data on average, data laggards see access fall to 30% or less, and only about half of organizations trust their AI agents' decisions. Meanwhile, insider selling at enterprise-AI bellwether C3.ai (CEO Thomas Siebel offloading $4.8M in shares) hints at investor caution layered under the adoption hype.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
JPMorgan Chase & Co.
Both facts report JPMorgan Chase & Co.'s revenue for the same fiscal period (FY 2025) with the same observation date (2025-12-31), but with different values: $182.447 billion vs. $185 billion. The ~1.4% difference ($2.553 billion) is too large to be explained by rounding alone and represents conflicting data for the identical time period.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,810
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,810 facts checked against source5,217 source documents archived
Work with this data → vianewsagency.com

METABOLIC EXPLORER Stock Over 21% Up In The Last 10 Sessions

Loading stream...

(vianews) - shares of metabolic explorer (cac 40: metex.pa) rose by a staggering 21.3% in 10 sessions from €0.98 to €1.19 at 05:06 est on tuesday, after three successive sessions in a row of gains. cac 40 is falling 1.01% to €7,314.05, following the last session's downward trend.

metabolic explorer's last close was €1.19, 72.52% under its 52-week high of €4.33.

about metabolic explorer

metabolic explorer s.a., a biological chemistry company, engages in the development and industrialization of industrial fermentation processes as alternatives to petrochemical processes worldwide. the company also offers propanediol, butyric acid, butyric acid, glycolic acid, amino acid, and l-valine. its products are used in the formulation of cosmetics, textiles, polymer, animal nutrition, and health products or as intermediates for the synthesis of biomaterials. the company was incorporated in 1999 and is based in saint-beauzire, france.

earnings per share

as for profitability, metabolic explorer has a trailing twelve months eps of €-1.14.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -39.56%.

yearly top and bottom value

metabolic explorer's stock is valued at €1.19 at 05:06 est, way under its 52-week high of €4.33 and way above its 52-week low of €0.88.

volatility

metabolic explorer's last week, last month's, and last quarter's current intraday variation average was a negative 0.57%, a positive 0.14%, and a positive 2.82%.

metabolic explorer's highest amplitude of average volatility was 3.04% (last week), 3.01% (last month), and 2.82% (last quarter).

more news about metabolic explorer (metex.pa).

METABOLIC EXPLORER Stock Over 21% Up In The Last 10 Sessions | ViaNews EU